Loading

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Drug or technology

SGLT2 inhibitor

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials1 Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 20, 2026 · PHASE 1 TRIAL

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

ClinicalTrials.gov

This is an early-phase, uncontrolled pharmacokinetic study in a small pediatric population designed to characterize drug dosing rather than efficacy, with no results yet reported.

PreliminaryDuchenne Muscular Dystrophy (DMD)NCT07172971 SGLT-2 inhibitor

Reported

Planned sample size10

PhasePhase 1

Primary outcome measureMedication dose

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support